UNSPSC 51312406: Methapyrilene fumarate

This classification denotes a histamine-1 receptor antagonist with the molecular structure 2C14H19N3S.3C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, KJ5I25TXYL chemically known as 1,2-ethanediamine, n,n-dimethyl-n'-2-pyridinyl-n'-(2-thienylmethyl)-, (e)-2-butenedioate (2:3), but more commonly known as methapyrilene fumarate, which bears US NIH Compound Identifier 6436730. European Medicines Agency schedules Methapyrilene fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14535MIG.

UNSPSC 51312406 Methapyrilene fumarate is a Commodity code, but the recent state and local opportunities posted under it do not involve methapyrilene fumarate or chemicals closely related to it. Instead, the code appears misapplied to pharmaceutical procurement activity — naloxone supply, direct-to-manufacturer prescription program market research, and generic multi-source pharmaceutical distribution contracts. The opportunities posted under this code reflect state and local health agencies and cooperative purchasing alliances sourcing finished pharmaceutical products and OTC goods through competitive procurement, not the specific active pharmaceutical ingredient the code nominally names. State and local governments are using this code tag inconsistently, and vendors evaluating activity here should treat the code as a poor signal for work in methapyrilene fumarate itself.

Recent opportunities span a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multi-state cooperative purchasing alliance (Minnesota MMCAP serving Minnesota, Oregon, and participating jurisdictions). Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly delivery to the county community health building; Texas HHS issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program before issuing a formal RFP; and Minnesota MMCAP released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. The geographic footprint spans Florida, Texas, and the upper Midwest, with cooperative-vehicle activity reaching multiple states.